EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration

Yu-Tzu Lin iD, Hsiu-Hsien Lin, Chih-Hao Chen, Kun-Hao Tseng, Mao-Wang Ho, Po-Ren Hsueh iD

Journal of Clinical Microbiology · 14.01.2026 · 64 (1)

DOI: 10.1128/jcm.01255-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 14.01.2026. Verfasst von Yu-Tzu Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Gram-Negative Bacteria, Disk Diffusion Antimicrobial Tests. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefiderocol (FDC) is a siderophore cephalosporin approved for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), including carbapenem-resistant (CR) isolates. However, interpretation criteria for both broth microdilution (BMD) and disk diffusion (DD) methods differ among Clinical and Laboratory Standards Institute (CLSI), European Committee on Antimicrobial Susceptibility Testing (EUCAST), and U.S. Food and Drug Administration (FDA) guidelines. This study aimed to assess the categorical agreement (CA) between minimum inhibitory concentrations (MICs) determined by the BMD method and inhibition zone diameters measured by the DD method for FDC, using different interpretive breakpoints across various Gram-negative bacilli (GNB) isolates. A total of 1,170 GNB isolates were collected, including CR and carbapenem-susceptible (CS) isolates of Escherichia coli , Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae complex, Pseudomonas aeruginosa , and Acinetobacter baumannii-calcoaceticus complex. Isolates of Stenotrophomonas maltophilia , Burkholderia cepacia , and Elizabethkingia anophelis —which are not categorized by carbapenem susceptibility—were also included. The CA and error rates (minor error, major error, and very major error) were calculated using MIC interpretation as the reference. Among CR isolates, CA based on CLSI breakpoints ranged from 90.0% to 100% across species. U.S. FDA criteria showed comparable performance, except for A. baumannii-calcoaceticus complex, where CA was lower (63.0%). In contrast, EUCAST breakpoints demonstrated greater variability, with CA ranging from 66.7% to 100%. Among CS isolates, CA was generally high (≥87.5%) across most standards and species, with exceptions including EUCAST in the E. cloacae complex (63.0%) and U.S. FDA in A. baumannii-calcoaceticus complex (73.7%). In conclusion, CLSI breakpoints demonstrated the highest consistency between DD and BMD methods. IMPORTANCE Cefiderocol is one of the few remaining treatment options for infections caused by carbapenem-resistant Gram-negative bacilli (GNB). Accurate interpretation of susceptibility testing is essential for guiding effective therapy. However, discrepancies among breakpoints established by the Clinical and Laboratory Standards Institute, the European Committee on Antimicrobial Susceptibility Testing, and the U.S. Food and Drug Administration may result in inconsistent interpretations, particularly when using the disk diffusion (DD) method, which is more practical in many clinical laboratories. This study compares the categorical agreement between broth microdilution and DD method interpretations for Gram-negative bacilli across multiple guidelines and highlights the potential for misclassification. It also provides susceptibility data for Burkholderia cepacia and Elizabethkingia anophelis , for which established interpretive criteria are currently lacking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsGram-Negative BacteriaDisk Diffusion Antimicrobial TestsCefiderocolMicrobial Sensitivity TestsUnited StatesHumansUnited States Food and Drug AdministrationEuropeGram-Negative Bacterial InfectionsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

antimicrobial susceptibility testingbreakpointscarbapenem-resistant Gram-negative bacillicefiderocol

Substanzen

Anti-Bacterial AgentsCefiderocolCephalosporins

Autor:innen und Institutionen

  • Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan.
  • Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.

ORCID-Profile: Yu-Tzu Lin, Po-Ren Hsueh

Zitieren

APA

Lin, Y. T., Lin, H. H., Chen, C. H., Tseng, K. H., Ho, M. W., & Hsueh, P. R. (2026). Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration. Journal of Clinical Microbiology, 64(1). https://doi.org/10.1128/jcm.01255-25

Vancouver

Lin YT, Lin HH, Chen CH, Tseng KH, Ho MW, Hsueh PR. Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration. Journal of Clinical Microbiology. 2026;64(1). doi:10.1128/jcm.01255-25

BibTeX
@article{Lin2026,
  author = {Lin, Yu-Tzu and Lin, Hsiu-Hsien and Chen, Chih-Hao and Tseng, Kun-Hao and Ho, Mao-Wang and Hsueh, Po-Ren},
  title = {Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  volume = {64},
  number = {1},
  doi = {10.1128/jcm.01255-25}
}
Kostenlos starten →